FTC sues big pharmacy profit professionals about insulin prices The agency brought action from Caremark, Categorical Scripts and Optum Rx, arguing their “anticompetitive and unfair” rebating practices “artificially inflated” the list price of daily life-conserving insulin prescription drugs. Insurers will continue vertically integrating to keep a lot more income in-property, https://kethek.com/